Webinar Deep Dive: Breaking the GLP-1 Cost Cycle VIDEO

The GLP-1 Shortage: What It Means and Why It Still Matters

Over the last few years, GLP-1 and GLP-1 receptor agonists like Ozempic, Wegovy, Mounjaro, and Zepbound gained widespread traction for tackling obesity and supporting long-term weight loss efforts*. They decrease appetite, regulate blood sugar, and deliver consistent weight loss results for individuals struggling to manage their metabolic health. However, with the surge in demand comes […]

By Noom Team

Employer Strategies for Maximizing the Promise of GLP-1s

The numbers are clear: 160 million adults in the U.S. want to improve their health and well-being through weight loss. As many employers already know, adding obesity management programs to health benefit plans can boost employee motivation and health outcomes. For those who are affected, reducing weight by just 5-10% can improve risk factors and […]

By Noom Team

Breaking the GLP-1 Cost Cycle

Noom’s Breaking the GLP-1 Cost Cycle white paper dives into the scale of the obesity crisis and how Noom’s two tailored solutions can enhance health outcomes and cost savings, including for those on GLP-1s or other anti-obesity medications.

By Noom Team